Robinson A G
N Engl J Med. 1976 Mar 4;294(10):507-11. doi: 10.1056/NEJM197603042941001.
DDAVP, 1-desamino-8-d-arginine-vasopressin, is a synthetic analogue of vasopressin with increased antidiuretic activity and decreased pressor activity. Whereas the antidiuretic-to-pressor ratio of arginine vasopressin is 1, the antidiuretic-to-pressor ratio of DDAVP is 4000. When administered as an intranasal spray, 5 to 20 mug of DDAVP produced eight to 20 hours of antidiuresis in patients with complete central diabetes insipidus. The minimum recommended therapeutic dose resulted in a maximum antidiuresis in most patients. No side effects of the drug were noted in clinical trials. DDAVP thus gives promise of becoming the standard treatment of severe central diabetes insipidus.
去氨加压素，即1-去氨基-8-D-精氨酸加压素，是一种加压素的合成类似物，其抗利尿活性增强而升压活性降低。精氨酸加压素的抗利尿与升压比为1，而去氨加压素的抗利尿与升压比为4000。经鼻喷雾给药时，5至20微克去氨加压素可使完全性中枢性尿崩症患者产生8至20小时的抗利尿作用。在大多数患者中，最小推荐治疗剂量产生了最大抗利尿效果。临床试验中未观察到该药物的副作用。因此，去氨加压素有望成为重度中枢性尿崩症的标准治疗方法。
